CTSO

CTSO

Cytosorbents Corporation Common Stock

$1.090+-0.000 (-0.000%)

Preço em tempo real

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$1.090

Máximo

$1.090

Mínimo

$1.090

Volume

0.01M

Fundamentos da empresa

Estatísticas de negociação

Notícias relacionadas

PR Newswire

CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...

Ver mais
CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025
Analyst Upgrades

D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains CytoSorbents with a Buy and maintains $10 price target.

Ver mais
D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
Analyst Upgrades

HC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target

HC Wainwright & Co. analyst Sean Lee reiterates CytoSorbents with a Neutral and maintains $1 price target.

Ver mais
HC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target
PR Newswire

CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...

Ver mais
CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update
Analyst Upgrades

D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains CytoSorbents with a Buy and maintains $10 price target.

Ver mais
D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target